Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study


Por: Navas-Moreno, V, Araujo-Castro, M, Tapia-Sanchiz, MS, Sebastián-Valles, F, Sampedro-Núñez, MA, de la Blanca, NS, Martínez-Hernández, R, Rodríguez-Laval, V, Blanco, C, Biagetti, B, Puig-Domingo, M and Marazuela, M

Publicada: 1 ene 2026
Resumen:
Background: Growth hormone and insulin-like growth factor 1 (IGF-1) have recently been linked to temporal muscle thickness (TMT) in acromegaly; however, the relationship between treatment response and TMT remains unclear. Objectives: To evaluate whether TMT correlates with treatment response and may serve as a surrogate marker of disease control in patients with acromegaly. Design: Retrospective longitudinal two-center study. Methods: Patients with acromegaly and non-functioning pituitary adenomas (NFPA) were included. TMT was measured on magnetic resonance imaging scans obtained before treatment initiation and after a 3-year follow-up. Baseline TMT was compared between groups. In patients with acromegaly, TMT was correlated with IGF-1 levels at diagnosis and over time, as well as with treatment response. Mixed-effects regression models adjusted for covariates were used to assess associations. Results: Imaging studies from 58 subjects were analyzed (40 with acromegaly, 18 with NFPA). Pre-treatment TMT was significantly greater in patients with acromegaly compared with NFPA (mean 10.1 mm (9.3-10.7) vs 8.1 mm (8.0-9.2), p = 0.003). Higher baseline TMT was associated with higher IGF-1 levels at diagnosis (p < 0.01). Following treatment, mean TMT decreased from 9.6 mm at baseline to 8.8 mm at 36 months (p = 0.001). In covariate-adjusted mixed-effects models, higher pre-treatment TMT was independently associated with increased IGF-1 levels at diagnosis and longitudinally (beta = 19.59 ng/mL, p = 0.022). Conclusion: TMT correlates with biochemical disease activity and decreases after treatment, suggesting it may be a useful imaging marker of clinical activity and prognosis in acromegaly.

Filiaciones:
Navas-Moreno, V:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

Araujo-Castro, M:
 Hosp Univ Ramon & Cajal, Dept Endocrinol & Nutr, Madrid, Spain

 Inst Invest Biomed Ramon & Cajal, Madrid, Spain

Tapia-Sanchiz, MS:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

Sebastián-Valles, F:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

Sampedro-Núñez, MA:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

de la Blanca, NS:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Raras CIBERER G, Madrid, Spain

Martínez-Hernández, R:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Raras CIBERER G, Madrid, Spain

Rodríguez-Laval, V:
 Hosp Univ Princesa, Dept Radiol, Madrid, Spain

Blanco, C:
 Principe Asturias Univ Hosp, Dept Endocrinol & Nutr, Madrid, Spain

Biagetti, B:
 Hosp Univ Vall Hebron, Endocrinol & Nutr Dept, CIBERER ISCIII U747, ENDO ERN, Barcelona, Spain

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias i Pujol, Endocrinol & Nutr Dept, CIBERER ISCIII U747, Badalona, Spain

Marazuela, M:
 Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
ISSN: 20420188





Therapeutic Advances in Endocrinology and Metabolism
Editorial
Sage Periodicals Press, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 17 Número:
Páginas:
WOS Id: 001749956900001
imagen gold

MÉTRICAS